Skip to main content
Springer logoLink to Springer
. 2021 May 27;14(6):759–773. doi: 10.1007/s40271-021-00526-y

Patient-Reported Experience and Outcome Measures in People Living with Diabetes: A Scoping Review of Instruments

Jimmy Martin-Delgado 1,2,3,, Mercedes Guilabert 4, José Mira-Solves 1,4,5
PMCID: PMC8563512  PMID: 34043215

Abstract

Background

Diabetes mellitus is a global public health concern, with over 463 million people living with this chronic disease. Pathology complexity, management difficulty, and limited participation in care has resulted in healthcare systems seeking new strategies to engage people living with diabetes. Patient-reported experience measures (PREMs) and patient-reported outcome measures (PROMs) were developed to address the gap between the healthcare system expectation and patient preference.

Objective

This study aimed to review the existing literature on PREMs and PROMs specific to type 1 and 2 diabetes, and report the dimensions report the dimensions they have measured.

Methods

A scoping review was conducted from January 1985 to March 2020 of six databases, MEDLINE, EMBASE, PsycINFO, CINHAL, Scopus, and BiblioPro, to identify PREM and PROM instruments specific for type 1 and 2 diabetes.

Results

Overall, 34 instruments were identified, 32 PROMs and two PREMs. The most common instrument included outcomes related to quality of life at 44% (n = 15), followed by satisfaction (whether with treatment, device, and healthy habits) at 26% (n = 9). Furthermore, instruments regarding personal well-being accounted for 15% (n = 5). For instruments that measure experiences of persons with diabetes, there were two scales of symptoms, and one related to the attitude patients have toward the disease.

Conclusions

Diabetes-specific validated instruments mainly focus on quality of life, education, and treatment, and sometimes overlap each other, in their subscales and assessment dimensions. Constructs such as cultural and religious beliefs, leisure, and work life may need more attention. There appears to be a gap in instruments to measure experiences of individuals who “live with diabetes” and seek to lead a “normal life.”

Supplementary Information

The online version contains supplementary material available at 10.1007/s40271-021-00526-y.

Key Points for Decision Makers

Disease-specific instruments are tailored to patient needs, avoiding irrelevancies from other generic measures.
It is vital to use an adequate instrument, with an adequate construct for measurement.
Patient-reported outcome measure instruments usually focus on patients’ quality of life; other aspects such as the social context should also be considered.
We found no cross-culturally validated or on-site developed instruments to be used in low-income and middle-income countries; more research is needed.

Introduction

Chronic non-communicable diseases pose a challenge for healthcare systems. The global prevalence of diabetes mellitus among adults (aged 20–79 years) was estimated at 9.3% (463 million people) in 2019, and is expected to rise to 10.2% (578 million) by 2030 [1]. Patient-centered care can be challenging to define, but common concepts are: disease and illness experience (patient-as-person), whole person (biopsychosocial perspective), common ground (sharing power and responsibility with healthcare provider), and patient-doctor relationship [2].

Since the 1990s, research has increasingly placed quality of life (QoL) in the spotlight, as an essential health outcome in diabetes, in some cases, if not “the ultimate goal” of treatment [3]. Currently, clinical trials should include the evaluation of the psychological aspects of patients, treatment satisfaction, well-being, and QoL, which are referred to as patient-reported outcome measures (PROMs) [4, 5]. For better intervention on health-disease processes, a patient with a chronic condition must be an active protagonist [6, 7]. Therefore, it is essential to incorporate the patient’s viewpoints into the organization of healthcare. Accordingly, it has been verified that when the patient perceives that his/her perspective, experience, and decisions about the illness are taken into account, there is more active and effective participation and cooperation in the treatment plan [8, 9]. The incorporation of instruments known as patient-reported experience measures (PREMs) has made it possible to make the patient visible within the context of the healthcare systems and include their experience in the management of chronic pathologies. The PREM and PROM instruments respond to the objectives of achieving patient-centered care.

Diabetes prevention and control are challenges for healthcare and social professionals, services, and systems. It also has a high economic and social impact [10]. The promotion of healthy lifestyles, the control of risk factors (diet, weight management, physical exercise), diabetes education, and patient self-care are essential elements in controlling the disease’s progression and the social and health burden it represents [11]. However, these are not the only factors that need to be considered. Significant evidence exists regarding the influence of psychosocial stress on risk factors, acceleration of disease, and overall health of individuals [12]. A recent study showed that daily stress related to work and an increased perceived risk of physical health may influence outcomes in diabetes care [13].

The experiences and results measured by patients change according to the local socio-cultural context. Healthcare systems and their results are not homogeneous and could change within the same region. Accordingly, it is necessary to understand how patients construct and interpret their disease. Healthcare systems need to adapt to patients’ needs, create a climate of trust, and act to improve adherence and the quality of care [14].

This study aimed to review disease-specific patient-reported outcomes and experience measures that currently exist for individuals with type 1 and 2 diabetes and what dimensions they measure. We attempt to provide a synthesis of these instruments for policy makers and researchers in order for them to choose the most suitable instrument for their intended purpose.

Methods

A scoping review of studies published in peer-reviewed journals was conducted. The Joanna Briggs Institute [15] protocol has been followed, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses—Extension for Scoping Reviews (PRISMA-ScR) checklist was used [16]. The study protocol is available from the corresponding author.

Inclusion Criteria

Studies specific to type 1 and 2 diabetes that collected, developed, or validated PROMs were included to examine: (a) QoL, (b) emotional stress, (c) symptoms, (d) adherence to treatment, and (e) satisfaction with treatment; and experience measures such as (1) living with diabetes and (2) the healthcare system. As there were no restrictions on age, the studies were selected from the young, adult, and older populations. Studies in both English and Spanish were included. Articles validating instruments on other diseases such as gestational diabetes, diabetic foot ulcers, selection of nutritional supplements, and other non-specific diseases such as high blood pressure, metabolic syndrome, or cardiovascular disease were excluded.

Data Sources and Search Strategy

The selected databases included MEDLINE, EMBASE, PsycINFO (via OvidSP), CINHAL, Scopus, and BiblioPro. The research team agreed on the terms and appropriately modified each database. The articles were limited to the English and Spanish languages, published between January 1985 and March 2020. Specific publication types were excluded from the search strategy, such as editorials and case reports. A combination of Medical Subject Headings (MeSH) and free‐text terms were used. Three groups of terms were generated to describe: (1) the population; (2) instruments, surveys, and PREMs/PROMs; and (3) psychometric properties. Terms within each group were combined with the Boolean operator “OR.” BiblioPro is a patient-reported measures database available in Spanish, and it was manually searched to look for possible instruments. In a complementary method, manual searches were performed in Google Scholar to identify the gray literature in different countries, which are not available in the already-mentioned scientific databases. The OvidSP database search is available in the Electronic Supplementary Material.

Selection of Reviewers

JMD conducted the search strategy in the databases. JMD and MG reviewed all titles and abstracts to identify potentially relevant studies. When a consensus was not achieved between both reviewers, a third researcher (JJM) reviewed the study and disagreements were addressed to reach a consensus. All the reviewers could read Spanish and English. Studies in the local language included an abstract that allowed the authors to decide if it had to be included for full-text reading. JMD and MG performed full-text reading of articles for inclusion. No unpublished studies were found, and neither was there a need to contact any of the authors included.

Data Extraction

Data extraction from each study was performed by all authors using a standardized Excel sheet. The sheet included the year of publication, whether PROM or PREM, number of items, outcome, dimensions, target population, mode of administration, recall period, number of participants, response options, range of scores, administration time, original language, and number of citations. Information about the design and the validation procedure used in each instrument was also included.

Data Synthesis

A qualitative and descriptive analysis of the data was conducted for each variable from which information was extracted. The researchers generated categories according to dimensions and its most recent definitions. The presence or absence of information in each variable was coded. Heterogeneity in the methods and measures applied was described when possible.

Quality Evaluation

The Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) checklist was employed to evaluate the studies’ methodological rigor [17]. The psychometric results reported in the studies were described and categorized into the COSMIN measurement properties.

Results

Overall, 8220 records were identified, of which 6003 remained after the exclusion of duplicates. After the review of titles and abstracts, 5783 studies were eliminated. Consequently, 220 articles were assessed with full-text reading, of which 193 were excluded, of these 173 were not diabetes-specific instruments, 15 did not include any patient-reported measure, four were related to ulcer foot care, and one was a nutritional scale. After the inclusion of two articles identified by searches of references, 29 articles meeting all inclusion criteria were included. Figure 1 shows this process of selecting studies.

Fig. 1.

Fig. 1

Preferred Reporting Items for Systematic Reviews and Meta-Analyses—Extension for Scoping Reviews (PRISMA-ScR) diagram. PREM patient-reported experience measure, PROM patient-reported outcome measure

Description of the Studies

Patient-reported outcome measure instruments were the most prevalent, accounting for 94% (n = 32) and PREM instruments, only 6% (n = 2). In the last 10 years, a notable increase was observed with the instruments, thus doubling the number. Regarding the instruments, outcomes related to QoL were the most common at 44% (n = 15), followed by those that measured satisfaction (whether with treatment, device, or healthy habits) at 26% (n = 9), and the well-being of the person accounted at 15% (n = 5). Two scales of symptoms associated with diabetes and one instrument related to the attitude of patients having the disease complete the selected outcome measures. Finally, only two instruments that measure the experiences of the person with diabetes were found. The number of items showed a high variability range from 7 to 41. Of these instruments, 13 were specific for application in type 2 diabetes, unlike 17 instruments used indistinctly in the two most common presentations of pathology (types 1 and 2), thereby leaving only four specific instruments for patients with type 1 diabetes. Most of the instruments were designed for the adult population, representing the 85% (n = 29). Table 1 shows the main characteristics of the selected instruments.

Table 1.

Overview of the included instruments

Instrument Year Type Items Outcomea Dimensions (subscales)a Diabetes type Target population
Decisional Balance for Insulin Injection (DBII) [26] 2019 PROM 13 Attitude

Advantages

Disadvantages

2 Adults
QoLHypo [27] 2018 PROM 13 QoL Impact of hypoglycemia on the health-related QoL 2 All ages
Diabetes Injection Device Experience Questionnaire (DID-EQ) [28] 2018 PROM 10 Satisfaction

Device characteristics

Global items

2 Adults
Swedish National Diabetes Register (SNDR) [29] 2018

PROM

PREM

33

Patient experience

Healthcare service experience

How you feel; worries; capabilities to care for your diabetes; barriers; support (family and friends); support (provider); medical services 1 and 2 Adults
Diabetes acceptance scale (DAS) [30] 2018 PROM 20 QoL Acceptance 1 and 2 Adults
Cuestionario ViDa con diabetes tipo 1 [31] 2017 PROM 34 Well-being Interference of diabetes in everyday life; self-care; well-being; worry about disease 1 All ages
DHP—3D [32] 2017 PROM 3 QoL Mood; eating; social limitations 2 Adults
DHP—5D [32] 2017 PROM 5 QoL Mood; eating; social limitations; hypoglycemic events; vitality 2 Adults
Diabetes Strengths and Resilience Measure for Adolescents with Type 1 Diabetes (DSTAR—Teen) [33] 2017 PROM 12 Well-being

Positive intrapersonal processes (confidence and coping)

Positive interpersonal processes (support and effective parental involvement)

1 Adolescents
Diabetes Intention, Attitude and Behavior Questionnaire (DIAB—Q) [23] 2016 PROM 17 QoL Intention to engage in self-care behaviors 2 Adults
Current Health Satisfaction Questionnaire (CHES-Q) [34] 2015 PROM 14 QoL

Current health

Knowledge of diabetes

2 Adults
National Diabetes Audit (NDA)—Patient Experience of Diabetes Services Survey [35] 2014 PREM 15 Healthcare service experience Care planning; care provision; healthcare checks 1 and 2 All ages
Diabetes self-management Questionnaire (DSMQ) [22] 2013 PROM 16 Satisfaction

Glucose management

Dietary control; physical activity; healthcare use

1 and 2 Adults
The Ability to Perform Physical Activities of Daily Living Questionnaire (APPADL) [36] 2012 PROM 7 QoL Self-reported ability to perform physical activities 2 Adults
Expectations about Insulin Therapy (EAITQ) [25] 2010 PROM 10 Satisfaction Expectation about insulin therapy; delivery system 2 Adults
Diabetes Symptom Checklist-Revised (DSC-R)[37] 2009 PROM 34 Symptom scale Symptomatology: hyperglycemic, hypoglycemic, psychological-cognitive, psychological-fatigue, cardiovascular, neurological-pain, neurological-sensory, and ophthalmologic 2 Adults
Treatment Related Impact Measure for Diabetes (TRIM-Diabetes) [24] 2009 PROM 28 Satisfaction Treatment burden; daily life; diabetes management; psychological health; compliance 1 and 2 insulin requiring Adults
TRIM-Diabetes Device [24] 2009 PROM 8 Satisfaction Device function; device bother 1 and 2 insulin requiring Adults
Diabetes Productivity Measure (DPM) [38] 2006 PROM 14 QoL Life and work productivity impairments 1 and 2 Adults
Diabetes Medication Satisfaction (Dia-MedSat) [38] 2006 PROM 21 Satisfaction Burden; efficacy; symptoms 1 and 2 Adults
Diabetes Symptom measure (DSM) [38] 2006 PROM 30 Symptoms High blood sugar; low blood sugar; neuropathy; general 1 and 2 Adults
Insulin Treatment satisfaction Questionnaire (ITSQ) [39] 2004 PROM 22 Satisfaction Inconvenience of regimen; lifestyle flexibility; hypoglycemic control; insulin delivery device; satisfaction 1 and 2 Adults
Diabetes Quality of Life Measure Brief Clinical Inventory (DQOL) [40] 2004 PROM 15 QoL Self-care behavior; satisfaction with diabetes control 1 and 2 Adults
Diabetes empowerment scale (DES) [41] 2000 PROM 28 Psychosocial self-efficacy Psychological aspects of diabetes; assessing dissatisfaction; readiness to change 1 and 2 Adults
Summary of Diabetes Self Care (SDSCA) [18] 2000 PROM 12 QoL Diet; exercise; self-analysis 2 Adults
Diabetes Health Profile (DHP - 18) [21] 2000 PROM 18 QoL Psychological distress; barriers to activity; disinhibited eating 2 Adults
ADDQoL [42] 1999 PROM 19 QoL QoL; social; work 1 and 2 Adults
Multidimensional Diabetes Questionnaire (MDQ) [43] 1997 PROM 41 QoL Perceptions related to diabetes and social support; positive and misguided reinforcing behaviors related to self-care; self-efficacy and outcome expectancies 2 Adults
Diabetes Fear of Injection and Self-testing Questionnaire (D-FISQ) [44] 1997 PROM 30 Satisfaction Fear of self-injecting; fear of self-testing 1 and 2 Adults
Diabetes Health Profile (DHP-1) [20] 1996 PROM 32 QoL Psychological distress; barriers to activity; disinhibited eating 1 Adults
Problem Areas in Diabetes Scale (PAID) [19] 1995 PROM 20 Well-being Depression; social support; health beliefs; coping style 1 and 2 Adults
Diabetes Treatment Satisfaction Questionnaires (DTSQ) [45] 1988 PROM 8 Satisfaction Treatment satisfaction; burden from hyperglycemia and hypoglycemia 1 and 2 All ages
Hypoglycemia Fear Survey [46] 1987 PROM 27 QoL Behavior; worry 1 Adults

PROM patient-reported outcome measure, PREM patient-reported experience measure, QoL quality of life

aAs reported by authors

English was the predominant language for the development of the selected instruments, accounting for 74% (n = 25). The most cited PROM is the Summary of Diabetes Self Care [18], and the sample size is heterogenous, with a range from 146 to 3594 participants in the included studies. Table 2 includes information related to the mode of administration, recall period, number of participants, response options, range of scores, administration time, original language, and the number of citations.

Table 2.

Selected studies characteristics

Instrument Mode of administration Recall period Participants Response options Range of scores Administration time, minutes Original language Number of citationsa
DBII [26] 332 Strongly disagree/strongly agree 1–5 Taiwanese 2
QoLHypo [27] Paper sheet 227 Never/always 0–2 Spanish 2
DID-EQ [28] Mail Present perception 142

Strongly disagree/strongly agree

Not at all confident/completely confident

Very dissatisfied/very satisfied

Very difficult/very easy

1–4 English 5
SNDR [29] Mail 972 Swedish 14
DAS [30] Paper sheet 2 weeks 606 Never true for me/always true for me 0–3 German 14
Cuestionario ViDa [31] Paper sheet 578 Strongly disagree/strongly agree 1–5 30 Spanish 7
DHP - 3D [32] Interview 150

Never/always

Very easy/not at all easy

0–3 English 4
DHP-– 5D [32] Interview 150

Never/always

Very easy/not at all easy

None of the time/all of the time

0–3 English 4
DSTAR-Teen [33] Online 260 Never/almost always 1–5 English 28
DIAB - Q [23] Online 1 week 1015

Strongly disagree/strongly agree

Not at all valuable/extremely valuable

1–7 English 10
CHES-Q [34] Online Present perception 1015 Strongly disagree/strongly agree 1–7 English 10
NDA [35] Online 12 months 714 English 21
DSMQ [22] 8 weeks 261 Does not apply to me/applies to me very much 0–3 German 269
APPADL [36] Paper sheet Present perception 146 Unable to do/not at all difficult 1–5 < 5 English 9
EAITQ [25] Paper sheet 240 Strongly disagree/strongly agree 1–7 English 9
DSC-R [37] Paper sheet 4 weeks 3594 Not at all/extremely 1–5 English 73
TRIM-D [24] Online 2 weeks 507

Not at all satisfied/extremely satisfied

Not at all convenient/extremely convenient

Never/almost never Interferes/almost Always/always interferes

1–5 5 English 65
TRIM-DD [24] Online 2 weeks 507 1–5 1 English 65
DPM [38] Online 409 < 2 English 88
Dia-MedSat [38] Online 409 4 English 88
DSM [38] Online 409 2 English 88
ITSQ [39] Online 4 weeks 402

No bother at all/a tremendous bother

Does not interfere at all/interferes tremendously

No planning at all/a tremendous amount of planning

Extremely confident/not at all confident

Not at all worried/extremely worried

1–7 English 112
Brief DQOL [40] Mail 498

Never/all the time

Very satisfied/very dissatisfied

1–5 English 150
DES [41] Mail 375 Strongly agree/ strongly disagree 1–5 English 693
SDSCA [18] Mail 7 days 127 How many days have you … 0–7 English 2400
DHP - 18 [21] Mail 426

Never/always

Never/very often

Not at all/very much

Very likely/not at all likely

0–3 7 English 97
ADDQoL [42] Paper sheet 154

A great deal better/a great deal worse

Increased a great deal/decreased a great deal

− 3 to + 3 English 678
MDQ [43] Mail 249 Not at all important/very important

0–6

0–100

French 225
D-FISQ [44] Mail Past month 266 Never/always 0–3 - Dutch 67
DHP-1 [20] Mail 2239

Never/always

Never/very often

Not at all/very much

Very likely/not at all likely

0–3 English 150
PAID [19] Paper sheet 451 No problem/serious problem 0–6 English 1251
DTSQ [45] Paper sheet Few weeks 219

Very dissatisfied/very satisfied

None of the time/most of the time

Very flexible/very inflexible

0–6 English 420
Hypoglycemia Fear Survey [46] Paper sheet 158 Never/very often 1–5 English 539

Please refer to Table 1 for the full instrument name

aAccording to Google Scholar

Dimensions

The selected instruments independently reported a total of 75 dimensions. Different constructs were included such as emotional distress, where the most commonly used instrument is Problem Areas in Diabetes (PAID) [19]. Healthy lifestyles and habits such as the Diabetes Health Profile 1 [20] and 18 [21], or the Diabetes Self-Management Questionnaire (DSMQ) [22]; patient education and engagement, where the Summary of Diabetes Self Care [18] and more recently the Diabetes Intention, Attitude and Behavior Questionnaire (DIAB-Q) [23] are conspicuous. Others were related to mobility, self-sufficiency in daily activities, treatment, emotional support (of the social circle or caregiver), and hypoglycemia or hyperglycemia symptoms. However, instruments specific to patients with type 1 diabetes tend to include questions related to satisfaction with the medical device, such as the Treatment Related Impact Measure for Diabetes Device (TRIM-DD) [24] or expectations about insulin treatment, and Expectations About Insulin Therapy (EAITQ) [25]. The other dimensions measured but in PREM instruments were patients’ perceived experience concerning healthcare, communication with the professional, care planning, care delivery, and patient-centered care. Table 3 includes a summary of all dimensions of selected instruments after review of instrument composition.

Table 3.

Dimensions reported in the selected instruments

Instrument Dimensions
QoL Emotional distress Lifestyle Education and engagement Treatmenta Support Social Medical services Symptoms
DBII [26]
QoLHypo [27]
DID-EQ [28]
SNDR [29] b
DAS [30]
Cuestionario ViDa [31]
DHP—3D [32]
DHP—5D [32]
DSTAR-Teen [33]
DIAB—Q [23]
CHES-Q [34]
NDA [35] b
DSMQ [22]
APPADL [36]
EAITQ [25]
DSC-R [37]
TRIM-D [24]
TRIM-DD [24]
DPM [38]
Dia-MedSat [38]
DSM [38]
ITSQ [39]
Brief DQOL [40]
DES [41]
SDSCA [18]
DHP—18 [21]
ADDQoL[42]
MDQ [43]
D-FISQ [44]
DHP-1 [20]
PAID [19]
DTSQ [45]
Hypoglycemia Fear Survey [46]

Please refer to Table 1 for the full instrument name

QoL quality of life

aTreatment satisfaction or dissatisfaction, satisfaction with device, satisfaction with insulin treatment, fear of self-testing

bStands for patient-reported experience measure dimensions; care planning, care provision, healthcare checks, and provider support

Quality Evaluation

The most frequently reported property was construct validity (n = 29), followed by content and criterion validity (n = 28), face validity (n = 20), and responsiveness (n = 17). Internal consistency was usually presented as Cronbach’s α (n = 25) with values of over > 0.70. In 16 studies, Cronbach’s α was presented as a single sum of the total scale and its dimensions, as opposed to nine studies that presented values for each of the dimensions. Test-retest was the least reported psychometric quality, only 15 studies (44%), and in most of the cases, authors reported the result of the intra-class correlation coefficient. Table 4 includes properties of each of the selected studies.

Table 4.

Evaluation of psychometric properties

Instrument Reliability Validity Responsiveness
Internal consistency Test-retest Face validity Content validity Criterion validity Construct validity
DBII [26] α = 0.78–0.92
QoLHypo [27] α = 0.901 ICC = 0.92
DID-EQ [28] α = 0.80 ICC = 0.92
SNDR [29] Weighted Kappa = 0.78
DAS [30] α = 0.96 r = 0.89
Cuestionario ViDa [31] α = 0.71–0.86 r = 0.78
DHP—3D [32]
DHP—5D [32]
DSTAR-Teen [33] α = 0.89 -
DIAB—Q [23] α = 0.30–0.68 ICC = 0.63–0.84
CHES-Q [34] ICC = 0.63–0.83
NDA [35]
DSMQ [22] α = 0.84
APPADL [36] α = 0.89 ICC = 0.91
EAITQ [25] α = 0.82 ICC = 0.80
DSC-R [37] α = 0.69–0.87
TRIM-D [24] α = 0.94 ICC = 0.85
TRIM-DD [24] α = 0.80 ICC = 0.89
DPM [38] α = 0.95

Dia-MedSat [38] α = 0.79–0.91
DSM [38] α = 0.95
ITSQ [39] α = 0.92 r = 0.94
Brief DQOL [40] α =0.85
DES [41] α = 0.96 ICC = 0.79
SDSCA [18] IIC = 0.20–0.77 ICC = 0.53
DHP—18 [21] α = 0.71–0.88
ADDQoL [42] α = 0.85
MDQ [43] α = 0.70–0.91
D-FISQ [44] α = 0.94
DHP-1 [20] α = 0.77–0.86
PAID [19] α = 0.95
DTSQ [45] α = 0.76
Hypoglycemia Fear Survey [46] α = 0.90 ICC = 0.89

Please refer to Table 1 for the full instrument name

α Cronbach α coefficient, ICC intra-class correlation coefficient, r Spearman rank correlation coefficient

Discussion

Undoubtedly, QoL and patients’ experiences and feelings should be assessed using qualitative methods, but we also need quantitative measures for clinical trials or for evaluating healthcare services [8, 47]. Outcome measures based on patient feedback are indispensable to move toward person-centered care. These metrics should cover all dimensions relevant to them. Patients with diabetes are often under significant psychological distress because of strict adherence to medications, changes in their daily activities, patterns such as diet and exercise, and fear of long-term macrovascular and microvascular complications, which will undermine their QoL [48].

Diabetes-related distress is defined as patients’ concerns about the self-management of diabetes, perception of support, emotional burden, and access to quality healthcare [49], and is associated with poorer glycemic control and QoL [5052]. This life experience of the individual with diabetes needs to be measured to provide strategies to cope with diabetes-related distress and properly achieve patient-centered care [53]. However, the traditional management and decisions made in diabetes have focused on reducing glycated hemoglobin levels for the prevention of long-term complications. This approach can incur in treatments that are complex and intrusive with the patient’s QoL. In the last two decades, attempts have been made to measure the relationship between glycemic control and psychosocial functioning [9, 54, 55].

The last disease-specific, health-related QoL systematic review for diabetes was conducted more than a decade ago [56]. Since then, research on PROMs has gained ground, doubling in number as shown in the present study. In this review, only specific diabetes instruments have been considered because these are tailored to meet patients’ needs. Generic instruments assess constructs or feelings relevant for anyone, leaving aside domains such as lifestyle flexibility or interference of diabetes in everyday life [57].

The correct use of the most appropriate instruments must be accurately determined by the researcher, focusing on the outcome pursued in the protocol [58]. Frequently, instruments are not appropriately selected for the purpose as explained by Speight et al. [3]. Additionally, we should also consider that dimensions can overlap. If we group the reported dimensions of the selected studies according to what they actually ask and measure, the characteristics would be as follows: lifestyle represents 20% (n = 14), treatment (includes satisfaction with treatment and devices) represents 18% (n = 13), emotional distress represents 17% (n = 12), education represents 15% (n = 11), QoL represents 10% (n = 7), social relations and support represent 13% (n = 9), and finally, others (includes general questions and symptoms) represent 4% (n = 3). Conversely, PREM instruments address patients’ perception of medical services, and the following dimensions were reported, care planning, care provision, healthcare checks, and support provided by healthcare professionals.

Among the most widely used PROMs for measuring the QoL of patients with diabetes are the ADDQoL, the WHO Well-Being questionnaire, and the EuroQoL-5D. However, two of these three are not specific to diabetes [3]. The three most cited scales are SDSCA (2400), PAID (1251), and DES (693). If we include ADDQoL, they mainly focus on healthy lifestyles, diabetes-related distress, and social support. Aspects such as whether individuals received integrated health and social care when required, how their occupational or leisure activities with friends and family are affected, or how their social and religious customs are respected within the framework of the healthcare they receive are areas that have not received sufficient attention in these instruments, although these are relevant issues for patients [59].

Research has predominantly focused on type 2 diabetes; in this review, only one PROM was specifically designed for adolescents with type 1 diabetes [33]. The psychometric properties of the included studies are reported in most of the instruments, and the administration time varies widely from 2 to 30 min. Nevertheless, this may not be enough, as 60% of them are paper based, and even though half of them have been developed in the last 10 years, online application has not taken over, and they do not seem to be systematically implemented. Barriers for proper implementation of PROMs have been identified, including time in the implementation process, lack of access and support in the inner setting, preparing an organization for implementation, especially training clinicians, and the inability of patients to complete instruments in the intervention process [60, 61].

Not all of the included studies considered patients during the development process of the instrument. To achieve person-centered care, individuals need to be part of the healthcare system and process. Qualitative studies have shown that the personal life experience of “living with diabetes” may be influenced by many barriers including social, economic, and cultural beliefs, personal factors, education, access to information, provider support, and medical treatment [62, 63].

Chronicity, defined as the combination of effects and complications that non-communicable diseases have on patients, is a challenge for all healthcare systems worldwide. Evaluation frameworks such as Triple AIM [64] or the Chronic Care Model [65] propose a shift in the measurement of outcomes and call for new metrics that incorporate health and social intervention experience and lifetime outcomes. The PREM and PROM instruments, such as those included in this review, have been widely used to assess these chronicity strategies implemented by healthcare services [35, 66, 67]. For people with diabetes, it is particularly relevant to address chronicity because of the comorbidity and impact of the disease on their QoL. These instruments can be used in both population-based and experimental studies focused on measuring an intervention’s effectiveness from the patient’s point of view. However, some of them, because of their length, may be impractical and have a more research-focused approach.

Undoubtedly, there are many instruments, developed in different countries by various healthcare systems or researchers, that mostly focus on patient satisfaction with their treatment, QoL, or fear of complications from treatment. Of these instruments, 78% were designed in the USA or the UK and were in English, the remainder in Spain (Spanish), Sweden (Swedish), Canada (French), the Netherlands (Dutch), and Germany (German). All of them were developed in high-income countries with strong economies and robust healthcare systems. Disease-specific measures are tailored to patient needs; it is not the same construct or feeling between different chronic diseases. To avoid irrelevancies that could cloud the picture, disease-specific measures will have a greater sensitivity. Generic measures (depressed mood, anxiety, energy, and positive well-being) may be common to everybody, but they will not remain constant across different conditions. Hyperglycemic and hypoglycemic episodes or chronic complications may disrupt these concepts and are confounded in people with diabetes [68]. Therefore, there might be a current need to develop diabetes-specific instruments in low-income and middle-income countries, where social, cultural and economic contexts and access to healthcare are different [69].

There were certain limitations in conducting this review. Despite diabetes being one of the most prevalent chronic non-communicable diseases, there is limited information about pathology-specific PREM instruments, unlike PROMs that have been widely developed over the past few years. This study only included variables related to diabetes, thus any other instrument that has not been specifically developed for patients with diabetes has not been included in the review process.

Conclusions

It is imperative to harmonize healthcare and direct our efforts in knowing the life experience of a patient in the face of his/her pathology. While there are specific validated instruments for people with diabetes, many of them overlap each other, in their subscales and assessment dimensions. The most developed instrument accounts for those related to education, QoL, and satisfaction, leaving the door open for the development of new instruments that measure the experience of a person who “lives with diabetes” and seeks to lead a “normal life.”

Supplementary Information

Below is the link to the electronic supplementary material.

Acknowledgements

We thank Dr. Jose M. Valderas for his valuable input into this study. Jimmy Martin-Delgado is supported by a Santiago Grisolia Scholarship (GrisoliaP/2018/158).

Declarations

Funding

This study was supported by Prometeu/2017/173 grant (Generalitat Valenciana, 2017).

Conflicts of Interest/Competing Interests

Jimmy Martin-Delgado, Mercedes Guilabert, and José Mira-Solves have no conflicts of interest that are directly relevant to the content of this article.

Ethics Approval

This study is part of a wider project with approval of the Ethics Committee of the Kennedy Clinical Hospital of Guayaquil (HCK-CEISH-19-0041).

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Availability of Data and Material

Data and material are available from the corresponding author upon reasonable request.

Code Availability

Not applicable.

Author’s Contributions

All authors contributed to the study conception and design. JM performed the literature search and database equations. JM and MG double checked the literature search results. Data analysis was performed by all the authors. The first draft was written by JM and MG. All authors critically revised the work and approved its final version for publication.

References

  • 1.Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843. [DOI] [PubMed] [Google Scholar]
  • 2.Hudon C, Fortin M, Haggerty JL, Lambert M, Poitras M-E. Measuring patients’ perceptions of patient-centered care: a systematic review of tools for family medicine. Ann Fam Med. 2011;9:155–164. doi: 10.1370/afm.1226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Speight J, Reaney MD, Barnard KD. Not all roads lead to Rome: a review of quality of life measurement in adults with diabetes. Diabet Med. 2009;26:315–327. doi: 10.1111/j.1464-5491.2009.02682.x. [DOI] [PubMed] [Google Scholar]
  • 4.Valderas JM, Alonso J. Patient reported outcome measures: a model-based classification system for research and clinical practice. Qual Life Res. 2008;17:1125–1135. doi: 10.1007/s11136-008-9396-4. [DOI] [PubMed] [Google Scholar]
  • 5.Deshpande P, Sudeepthi BL, Rajan S, Abdul NC. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res. 2011;2:137–144. doi: 10.4103/2229-3485.86879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kinmonth AL, Spiegal N, Woodcock A. Developing a training programme in patient-centred consulting for evaluation in a randomised controlled trial; diabetes care from diagnosis in British primary care. Patient Educ Couns. 1996;29:75–86. doi: 10.1016/0738-3991(96)00936-6. [DOI] [PubMed] [Google Scholar]
  • 7.Stewart M, Brown JB, Boon H, Galajda J, Meredith L, Sangster M. Evidence on patient-doctor communication. Cancer Prev Control. 1999;3:25–30. [PubMed] [Google Scholar]
  • 8.Pyatak EA, Carandang K, Vigen CLP, Blanchard J, Diaz J, Concha-Chavez A, et al. Occupational therapy intervention improves glycemic control and quality of life among young adults with diabetes: the Resilient, Empowered, Active Living with Diabetes (REAL Diabetes) randomized controlled trial. Diabetes Care. 2018;41:696–704. doi: 10.2337/dc17-1634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Svedbo Engström M, Leksell J, Johansson U-B, Borg S, Palaszewski B, Franzén S, et al. Health-related quality of life and glycaemic control among adults with type 1 and type 2 diabetes: a nationwide cross-sectional study. Health Qual Life Outcomes. 2019;17:141. doi: 10.1186/s12955-019-1212-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Vandenberghe D, Albrecht J. The financial burden of non-communicable diseases in the European Union: a systematic review. Eur J Public Health. 2020;30:833–839. doi: 10.1093/eurpub/ckz073. [DOI] [PubMed] [Google Scholar]
  • 11.Barceló A, Cafiero E, de Boer M, Mesa AE, Lopez MG, Jiménez RA, et al. Using collaborative learning to improve diabetes care and outcomes: the VIDA project. Prim Care Diabetes. 2010;4:145–153. doi: 10.1016/j.pcd.2010.04.005. [DOI] [PubMed] [Google Scholar]
  • 12.Epel ES, Crosswell AD, Mayer SE, Prather AA, Slavich GM, Puterman E, et al. More than a feeling: a unified view of stress measurement for population science. Front Neuroendocrinol. 2018;49:146–169. doi: 10.1016/j.yfrne.2018.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Walker RJ, Garacci E, Campbell JA, Egede LE. The influence of daily stress on glycemic control and mortality in adults with diabetes. J Behav Med. 2020;43:723–731. doi: 10.1007/s10865-019-00109-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bolaño E, Sarría A. Prespectiva de los pacientes sobre la diabetes tipo 2 y relación con los profesionales sanitarios de atención primaria. Rev Orig la Univ Alcalá. 2003;32:1–8. doi: 10.1016/S0212-6567(03)79251-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015;13:132–140. doi: 10.1097/XEB.0000000000000055. [DOI] [PubMed] [Google Scholar]
  • 16.Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467–473. doi: 10.7326/M18-0850. [DOI] [PubMed] [Google Scholar]
  • 17.Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19:539–549. doi: 10.1007/s11136-010-9606-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care J. 2000;23:943–950. doi: 10.2337/diacare.23.7.943. [DOI] [PubMed] [Google Scholar]
  • 19.Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Aponte JE, et al. Assessment of diabetes-related distress. Diabetes Care. 1995;18:754–760. doi: 10.2337/diacare.18.6.754. [DOI] [PubMed] [Google Scholar]
  • 20.Meadows K, Steen N, McColl E, Eccles M, Shiels C, Hewison J, et al. The diabetes health profile (DHP): a new instrument for assessing the psychosocial profile of insulin requiring patients: development and psychometric evaluation. Qual Life Res. 1996;5:242–254. doi: 10.1007/BF00434746. [DOI] [PubMed] [Google Scholar]
  • 21.Meadows KA, Abrams C, Sandbæk A. Adaptation of the Diabetes Health Profile (DHP-1) for use with patients with type 2 diabetes mellitus: psychometric evaluation and cross-cultural comparison. Diabet Med. 2000;17:572–580. doi: 10.1046/j.1464-5491.2000.00322.x. [DOI] [PubMed] [Google Scholar]
  • 22.Schmitt A, Gahr A, Hermanns N, Kulzer B, Huber J, Haak T. The Diabetes Self-Management Questionnaire (DSMQ): development and evaluation of an instrument to assess diabetes self-care activities associated with glycaemic control. Health Qual Life Outcomes. 2013;11:138. doi: 10.1186/1477-7525-11-138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Traina SB, Mathias SD, Colwell HH, Crosby RD, Abraham C. The Diabetes Intention, Attitude, and Behavior Questionnaire: evaluation of a brief questionnaire to measure physical activity, dietary control, maintenance of a healthy weight, and psychological antecedents. Patient Prefer Adherence. 2016;10:213–222. doi: 10.2147/PPA.S94878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Brod M, Hammer M, Christensen T, Lessard S, Bushnell DM. Understanding and assessing the impact of treatment in diabetes: The treatment-related impact measures for diabetes and devices (TRIM-Diabetes and TRIM-Diabetes Device) Health Qual Life Outcomes. 2009;7:83. doi: 10.1186/1477-7525-7-83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Naegeli AN, Hayes RP. Expectations about and experiences with insulin therapy contribute to diabetes treatment satisfaction in insulin-naïve patients with type 2 diabetes. Int J Clin Pract. 2010;64:908–916. doi: 10.1111/j.1742-1241.2010.02363.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hsu H-C, Chen S-Y, Huang Y-C, Wang R-H, Lee Y-J, An L-W, et al. Decisional balance for insulin injection: scale development and psychometric testing. J Nurs Res. 2019;27:e42. doi: 10.1097/jnr.0000000000000316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Orozco-Beltrán D, Artola S, Jansà M, de la Torre-Casares ML, Fuster E. Impact of hypoglycemic episodes on health-related quality of life of type-2 diabetes mellitus patients: development and validation of a specific QoLHYPO© questionnaire. Health Qual Life Outcomes. 2018;16:52. doi: 10.1186/s12955-018-0875-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Matza LS, Boye KS, Stewart KD, Paczkowski R, Jordan J, Murray LT. Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ) J Patient Rep Outcomes. 2018;2:43. doi: 10.1186/s41687-018-0068-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Svedbo Engström M, Leksell J, Johansson UB, Eeg-Olofsson K, Borg S, Palaszewski B, et al. A disease-specific questionnaire for measuring patient-reported outcomes and experiences in the Swedish National Diabetes Register: development and evaluation of content validity, face validity, and test-retest reliability. Patient Educ Couns. 2018;101:139–146. doi: 10.1016/j.pec.2017.07.016. [DOI] [PubMed] [Google Scholar]
  • 30.Schmitt A, Reimer A, Kulzer B, Icks A, Paust R, Roelver KM, et al. Measurement of psychological adjustment to diabetes with the diabetes acceptance scale. J Diabetes Complicat. 2018;32:384–392. doi: 10.1016/j.jdiacomp.2018.01.005. [DOI] [PubMed] [Google Scholar]
  • 31.Alvarado-Martel D, Ruiz Fernández MA, Vigaray MC, Carrillo A, Boronat M, Montesdeoca AE, et al. ViDa1: the development and validation of a new questionnaire for measuring health-related quality of life in patients with type 1 diabetes. Front Psychol. 2017;8:1–14. doi: 10.3389/fpsyg.2017.00904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Mulhern B, Labeit A, Rowen D, Knowles E, Meadows K, Elliott J, et al. Developing preference-based measures for diabetes: DHP-3D and DHP-5D. Diabet Med. 2017;34:1264–1275. doi: 10.1111/dme.13377. [DOI] [PubMed] [Google Scholar]
  • 33.Hilliard ME, Iturralde E, Weissberg-Benchell J, Hood KK. The Diabetes strengths and resilience measure for adolescents with type 1 diabetes (DSTAR-Teen): validation of a new, brief self-report measure. J Pediatr Psychol. 2017;42:995–1005. doi: 10.1093/jpepsy/jsx086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Traina SB, Colwell HH, Crosby RD, Mathias SD. Pragmatic measurement of health satisfaction in people with type 2 diabetes mellitus using the Current Health Satisfaction Questionnaire. Patient Relat Outcome Meas. 2015;6:103–115. doi: 10.2147/PROM.S79368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.The Health and Social Care Information Centre. National diabetes audit 2013–14: patient experience of Diabetes Services Survey Pilot. 2014. https://files.digital.nhs.uk/publicationimport/pub14xxx/pub14211/nda-peds-pil-13-14-rep.pdf. Accessed 17 Jan 2020.
  • 36.Hayes RP, Schultz EM, Naegeli AN, Curtis BH. Test–retest, responsiveness, and minimal important change of the ability to perform physical activities of daily living questionnaire in individuals with type 2 diabetes and obesity. Diabetes Technol Ther. 2012;14:1118–1125. doi: 10.1089/dia.2012.0123. [DOI] [PubMed] [Google Scholar]
  • 37.Arbuckle RA, Humphrey L, Vardeva K. Psychometric evaluation of the Diabetes Symptom Checklist-Revised (DSC-R): a measure of symptom distress. Value Health. 2009;12:1168–1175. doi: 10.1111/j.1524-4733.2009.00571.x. [DOI] [PubMed] [Google Scholar]
  • 38.Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res. 2006;15:481–491. doi: 10.1007/s11136-005-1624-6. [DOI] [PubMed] [Google Scholar]
  • 39.Anderson RT, Skovlund SE, Marrero D, Levine DW, Meadows K, Brod M, et al. Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther. 2004;26:565–578. doi: 10.1016/S0149-2918(04)90059-8. [DOI] [PubMed] [Google Scholar]
  • 40.Burroughs TE, Desikan R, Waterman BM, Gilin D, McGill J. Development and validation of the Diabetes Quality of Life Brief Clinical Inventory. Diabetes Spectr. 2004;17:41–49. doi: 10.2337/diaspect.17.1.41. [DOI] [Google Scholar]
  • 41.Anderson RM, Funnel MM, Fitzgerald JT, Marrero DG. The Diabetes Empowerment Scale. Diabetes Care. 2000;23:739–743. doi: 10.2337/diacare.23.6.739. [DOI] [PubMed] [Google Scholar]
  • 42.Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res. 1999;8:79–91. doi: 10.1023/A:1026485130100. [DOI] [PubMed] [Google Scholar]
  • 43.Talbot F, Nouwen A, Gingras J, Gosselin M, Audet J. The assessment of diabetes-related cognitive and social factors: the multidimensional diabetes questionnaire. J Behav Med. 1997;20:291–312. doi: 10.1023/A:1025508928696. [DOI] [PubMed] [Google Scholar]
  • 44.Snoek FJ, Mollema ED, Heine RJ, Bouter LM, Van Der Ploeg HM. Development and validation of the diabetes fear of injecting and self- testing questionnaire (D-FISQ): first findings. Diabet Med. 1997;14:871–876. doi: 10.1002/(SICI)1096-9136(199710)14:10&#x0003c;871::AID-DIA457&#x0003e;3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  • 45.Lewis KS, Bradley C, Knight G, Boulton AJM, Ward JD. A measure of treatment satisfaction designed specifically for people with insulin-dependent diabetes. Diabet Med. 1988;5:235–242. doi: 10.1111/j.1464-5491.1988.tb00976.x. [DOI] [PubMed] [Google Scholar]
  • 46.Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care. 1987;10:617–621. doi: 10.2337/diacare.10.5.617. [DOI] [PubMed] [Google Scholar]
  • 47.Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus. JAMA. 1998;280:1490–1496. doi: 10.1001/jama.280.17.1490. [DOI] [PubMed] [Google Scholar]
  • 48.Polonsky WH. Emotional and quality-of-life aspects of diabetes management. Curr Diab Rep. 2002;2:153–159. doi: 10.1007/s11892-002-0075-5. [DOI] [PubMed] [Google Scholar]
  • 49.Fisher L, Mullan JT, Arean P, Glasgow RE, Hessler D, Masharani U. Diabetes distress but not clinical depression or depressive symptoms is associated with glycemic control in both cross-sectional and longitudinal analyses. Diabetes Care. 2010;33:23–28. doi: 10.2337/dc09-1238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Lim SM, Siaw MYL, Tsou KYK, Kng KK, Lee JY-C. Risk factors and quality of life of patients with high diabetes-related distress in primary care: a cross-sectional, multicenter study. Qual Life Res. 2019;28:491–501. doi: 10.1007/s11136-018-1994-1. [DOI] [PubMed] [Google Scholar]
  • 51.Strandberg RB, Graue M, Wentzel-Larsen T, Peyrot M, Rokne B. Relationships of diabetes-specific emotional distress, depression, anxiety, and overall well-being with HbA1c in adult persons with type 1 diabetes. J Psychosom Res. 2014;77:174–179. doi: 10.1016/j.jpsychores.2014.06.015. [DOI] [PubMed] [Google Scholar]
  • 52.Van Bastelaar KMP, Pouwer F, Geelhoed-Duijvestijn PHLM, Tack CJ, Bazelmans E, Beekman AT, et al. Diabetes-specific emotional distress mediates the association between depressive symptoms and glycaemic control in type 1 and type 2 diabetes. Diabet Med. 2010;27:798–803. doi: 10.1111/j.1464-5491.2010.03025.x. [DOI] [PubMed] [Google Scholar]
  • 53.Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39:2126–2140. doi: 10.2337/dc16-2053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Lau CY, Qureshi AK, Scott SG. Association between glycaemic control and quality of life in diabetes mellitus. J Postgrad Med. 2004;50:189–193. [PubMed] [Google Scholar]
  • 55.Ishii H, Niiya T, Ono Y, Inaba N, Jinnouchi H, Watada H. Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study. Diabetol Metab Syndr. 2017;9:3. doi: 10.1186/s13098-016-0202-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.El Achhab Y, Nejjari C, Chikri M, Lyoussi B. Disease-specific health-related quality of life instruments among adults diabetic: a systematic review. Diabetes Res Clin Pract. 2008;80:171–184. doi: 10.1016/j.diabres.2007.12.020. [DOI] [PubMed] [Google Scholar]
  • 57.Norris SL, McNally TK, Zhang X, Burda B, Chan B, Chowdhury FM, et al. Published norms underestimate the health-related quality of life among persons with type 2 diabetes. J Clin Epidemiol. 2011;64:358–365. doi: 10.1016/j.jclinepi.2010.04.016. [DOI] [PubMed] [Google Scholar]
  • 58.Fisher L, Tang T, Polonsky W. Assessing quality of life in diabetes: I. A practical guide to selecting the best instruments and using them wisely. Diabetes Res Clin Pract. 2017;126:278–285. doi: 10.1016/j.diabres.2016.10.018. [DOI] [PubMed] [Google Scholar]
  • 59.Mira JJ, Nuño-Solinís R, Guilabert-Mora M, Solas-Gaspar O, Fernández-Cano P, González-Mestre MA, et al. Development and validation of an instrument for assessing patient experience of chronic illness care. Int J Integr Care. 2016;16:13. doi: 10.5334/ijic.2443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Briggs MS, Rethman KK, Crookes J, Cheek F, Pottkotter K, McGrath S, et al. Implementing patient-reported outcome measures in outpatient rehabilitation settings: a systematic review of facilitators and barriers using the consolidated framework for implementation research. Arch Phys Med Rehabil. 2020;101:1796–1812. doi: 10.1016/j.apmr.2020.04.007. [DOI] [PubMed] [Google Scholar]
  • 61.Foster A, Croot L, Brazier J, Harris J, O’Cathain A. The facilitators and barriers to implementing patient reported outcome measures in organisations delivering health related services: a systematic review of reviews. J Patient Rep Outcomes. 2018;2:46. doi: 10.1186/s41687-018-0072-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Engström MS, Leksell J, Johansson U-B, Gudbjörnsdottir S. What is important for you? A qualitative interview study of living with diabetes and experiences of diabetes care to establish a basis for a tailored patient-reported outcome measure for the Swedish National Diabetes Register. BMJ Open. 2016;6:e010249. doi: 10.1136/bmjopen-2015-010249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Wilkinson A, Whitehead L, Ritchie L. Factors influencing the ability to self-manage diabetes for adults living with type 1 or 2 diabetes. Int J Nurs Stud. 2014;51:111–122. doi: 10.1016/j.ijnurstu.2013.01.006. [DOI] [PubMed] [Google Scholar]
  • 64.Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Aff. 2008;27:759–769. doi: 10.1377/hlthaff.27.3.759. [DOI] [PubMed] [Google Scholar]
  • 65.Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank Q. 1996;74:511–544. doi: 10.2307/3350391. [DOI] [PubMed] [Google Scholar]
  • 66.Coleman K, Austin BT, Brach C, Wagner EH. Evidence on the chronic care model in the new millennium. Health Aff. 2009;28:75–85. doi: 10.1377/hlthaff.28.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Borg S, Eeg-Olofsson K, Palaszewski B, Engström MS, Gerdtham U-G, Gudbjörnsdottir S. Patient-reported outcome and experience measures for diabetes: development of scale models, differences between patient groups and relationships with cardiovascular and diabetes complication risk factors, in a combined registry and survey study in Sweden. BMJ Open. 2019;9:e025033. doi: 10.1136/bmjopen-2018-025033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Bradley C. Handbook of psychology and diabetes. 1. London: Routledge; 1994. [Google Scholar]
  • 69.Mills A. Health care systems in low- and middle-income countries. N Engl J Med. 2014;370:552–557. doi: 10.1056/NEJMra1110897. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from The Patient are provided here courtesy of Springer

RESOURCES